Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the ... trader reveals his one-line chart technique ...

Crucially, the top-line reduction differed ... CagriSema seems to have fallen short of Novo Nordisk's view that the drug would be a next-generation obesity product that would be tough for rivals ...

Other senior executives, including chief product officer Gustav Söderström and chief human resources officer Katarina Berg, also took advantage of the surge by offloading substantial stock holdings.

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and is in pole position to benefit from strong near-term demand for new weight ...

It hasn't been a great period for investors in Novo Nordisk (NYSE ... that Wegovy is actually more effective than the other product. As of Dec. 4, there's no reason for it to be that confident ...